This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Triple Negative Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Stomach Neoplasms
- Colorectal Neoplasms
- Ovarian Neoplasms
- Prostatic Neoplasms
- Uterine Cervical Neoplasms
- Melanoma
- Carcinoma, Transitional Cell
Age: 18 years - 66+
Gender: All